Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy

作     者：Bin-Bin Li Bo Wang Cheng-Ming Zhu Di Tang Jun Pang Jing Zhao Chun-Hui Sun Miao-Juan Qiu Zhi-Rong Qian Li Bin-Bin;Wang Bo;Zhu Cheng-Ming;Tang Di;Pang Jun;Zhao Jing;Sun Chun-Hui;Qiu Miao-Juan;Qian Zhi-Rong

作者机构：School of Biological SciencesNanyang Technological UniversitySingapore 639798Singapore Scientific Research CenterThe Seventh Affiliated HospitalSun Yat-sen UniversityShenzhenGuangdong 518107China Equipe Communication Intercellulaire et Infections MicrobiennesCentre de Recherche Interdisciplinaire en Biologie(CIRB)College de FranceParis 75005France 

出 版 物：《Chronic Diseases and Translational Medicine》 (慢性疾病与转化医学（英文版）)

年 卷 期：2019年第5卷第3期

页      面：155-169页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：THZ1 Cyclin-dependent kinase 7 Cancer therapy Transcription Super-enhancer 

摘      要：Current cancer therapies have encountered adverse response due to poor therapeutic efficiency,severe side effects and acquired resistance to multiple ***,there are urgent needs for finding new cancer-targeted pharmacological *** this review,we summarized the current understanding with THZ1,a covalent inhibitor of cyclin-dependent kinase 7(CDK7),which demonstrated promising anti-tumor activity against different cancer *** introducing the anti-tumor behaviors and the potential targets for different cancers,this review aims to provide more effective approaches to CDK7 inhibitor-based therapeutic agents and deeper insight into the diverse tumor proliferation mechanisms.